SCHEMBL4897533

SCHEMBL4897533

CC(C)Oc1ccc2c(c1)-c1cc(OC(C)C)ccc1C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.45
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 1/20 0.42
PARP10 Q53GL7 1/20 0.41
BRD4 O60885 1/20 0.41
BRPF1 P55201 1/20 0.41
PDK2 Q15119 1/20 0.41
HTR2C P28335 4/20 0.40
HTR2A P28223 3/20 0.40
METAP1 P53582 1/20 0.40
ALDH1A3 P47895 1/20 0.39
POLB P06746 1/20 0.39
GLA P06280 1/20 0.38
EZH2 Q15910 1/20 0.38
TP53 P04637 2/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895426 0.88 ALDH1A1 (0.44) CES2ALDH1A1KMT2APARP10BRD4
SCHEMBL15395721 0.83 MAPT (0.50) ALDH1A1PDK2HTR2CLMNAMAPK1
SCHEMBL31638161 0.82 CES2 (0.54) CES2ALDH1A1KMT2APARP10BRD4
SCHEMBL4898371 0.81 FFAR4 (0.41) CES2BRD4HTR2CHTR2AMETAP1
SCHEMBL6766300 0.79 MAOA (0.56) CES2ALDH1A1KMT2APDK2HTR2C
SCHEMBL21732515 0.77 ALDH1A1 (0.46) ALDH1A1KMT2APARP10BRD4BRPF1
SCHEMBL31638292 0.76 BRD4 (0.50) CES2ALDH1A1KMT2APARP10BRD4
SCHEMBL30218157 0.76 METAP1 (0.46) CES2ALDH1A1KMT2APARP10BRD4
SCHEMBL4895916 0.76 METAP1 (0.61) ALDH1A1KMT2AHTR2CHTR2AMETAP1
SCHEMBL8601747 0.74 HTR2C (0.80) HTR2CHTR2AEZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101107260-B Transition metal complex, method for producing the same, substituted fluorene compound, method for producing the substituted fluorene compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and method for producing olefin polymer SUMITOMO CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-8084559-B2 Ethylene-vinylcyclohexane copolymers SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-27 US disclosed
US-20080161514-A1 Transition Metal Complex, Process For Producing Said Transition Metal Complex, Substituent-Carrying Fluorene Compound, Process For Producing Said Fluorene Compound, Catalyst Component For Olefin Polymerization, Catalyst For Olefin Polymerization, and Process For Producing Olefin Polymer SUMITOMO CHEMICAL COMPANY, LIMTIED (JP) 2008-07-03 US disclosed
CN-101107260-A Transition metal complex, method for producing the same, substituted fluorene compound, method for producing the substituted fluorene compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and method for producing olefin polymer SUMITOMO CHEMICAL CO (JP) 2008-01-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161514-A1 Transition Metal Complex, Process For Producing Said Transition Metal Complex, Substituent-Carrying Fluorene Compound, Process For Producing Said Fluorene Compound, Catalyst Component For Olefin Polymerization, Catalyst For Olefin Polymerization, and Process For Producing Olefin Polymer AOC2, ACSL1, ACSL3 CES2 2015/4885ALDH1A1 1292/4885KMT2A 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.